Dupixent (dupilumab) works by blocking a specific receptor on cells that drives allergic inflammation. It’s a lab-made antibody that attaches to a protein called IL-4 receptor alpha, which sits on the surface of immune cells. By locking onto this receptor, Dupixent prevents two key inflammatory signaling molecules, IL-4 and IL-13, from delivering their messages. This interrupts a chain reaction responsible for conditions like eczema, asthma, nasal polyps, and several other allergic diseases.
The Inflammatory Pathway Dupixent Targets
Your immune system has different modes of response. One of these, called type 2 inflammation, is the branch that reacts to allergens and parasites. In people with conditions like atopic dermatitis or asthma, this branch is overactive. It churns out inflammatory signals even when there’s no real threat, causing skin rashes, airway swelling, excess mucus, and intense itching.
Two signaling molecules sit at the center of this overreaction: IL-4 and IL-13. Think of them as chemical messengers that tell immune cells to ramp up the allergic response. They do this by docking onto receptors on cell surfaces, much like a key fitting into a lock. Both IL-4 and IL-13 share one critical lock component: the IL-4 receptor alpha chain. Dupixent binds to that shared component and physically blocks both messengers from connecting. Without that connection, the downstream cascade of allergic inflammation slows dramatically.
What Changes in Your Body After Blocking IL-4 and IL-13
Once Dupixent cuts off IL-4 and IL-13 signaling, several things happen at the cellular level that translate into symptom relief:
- IgE production drops. IL-4 normally instructs certain immune cells (B cells) to produce IgE, the antibody responsible for allergic reactions. Dupixent interrupts that instruction. Total IgE levels in the blood decline gradually over weeks to months of treatment.
- Fewer inflammatory cells migrate to affected tissues. IL-4 and IL-13 trigger the release of chemical signals that recruit eosinophils and other inflammatory cells into the skin, airways, or gut lining. Blocking these cytokines reduces levels of those recruiting signals, including compounds called TARC and eotaxin-3, which drop rapidly after treatment begins.
- Tissue remodeling slows. In conditions like asthma and nasal polyps, chronic inflammation causes structural changes: thickened airway walls, polyp growth, skin barrier breakdown. By calming the underlying inflammation, Dupixent helps slow or partially reverse these changes over time.
Some of these effects happen quickly. Blood markers of type 2 inflammation like TARC and eotaxin-3 begin falling within the first few weeks. Others, like total IgE reduction, are more gradual and continue declining over months of treatment. The drug reaches steady-state concentration in the body by about week 16.
Conditions Dupixent Is Approved to Treat
Because type 2 inflammation underlies a wide range of allergic and inflammatory diseases, Dupixent’s approval list has grown substantially since its initial launch for eczema. It is currently FDA-approved for eight conditions:
- Atopic dermatitis (eczema) in patients 6 months and older with moderate to severe disease
- Asthma with an eosinophilic pattern or oral steroid dependence, in patients 6 years and older
- Chronic rhinosinusitis with nasal polyps in patients 12 and older
- Eosinophilic esophagitis in patients 1 year and older weighing at least 15 kg
- Prurigo nodularis in adults
- Chronic obstructive pulmonary disease (COPD) with an eosinophilic pattern, in adults
- Chronic spontaneous urticaria (hives) in patients 12 and older
- Bullous pemphigoid in adults
In every case, Dupixent targets the same receptor and the same underlying inflammatory process. The conditions differ in where the inflammation shows up (skin, lungs, sinuses, esophagus), but the immunological driver is shared.
How Dupixent Is Taken
Dupixent is a subcutaneous injection, meaning it goes just under the skin rather than into a vein or muscle. Most people self-inject at home using a prefilled syringe or autoinjector pen. You can inject into the thigh, the outer upper arm, or the abdomen (avoiding the two-inch area around the navel). Rotating the injection site each time helps prevent skin irritation at any one spot.
For adults with atopic dermatitis, the typical schedule is a loading dose of 600 mg (given as two separate 300 mg injections on day one), followed by 300 mg every two weeks. For asthma, the dose may be 200 mg or 300 mg every two weeks depending on whether you also have eczema or take oral corticosteroids. Pediatric doses are weight-based and adjusted by condition. Each injection takes only a few minutes, and the every-other-week schedule is consistent across most indications.
Common Side Effects
Because Dupixent targets a narrow part of the immune system rather than broadly suppressing it, its side effect profile is relatively mild compared to older immunosuppressants. The most notable side effect is conjunctivitis, or eye inflammation, which occurs more frequently in people using Dupixent for atopic dermatitis than for other conditions. In adult eczema trials, between 8% and 19% of patients on Dupixent developed conjunctivitis, compared with lower rates on placebo. In trials for asthma, nasal polyps, eosinophilic esophagitis, and other conditions, conjunctivitis rates were under 5% and similar to placebo.
Injection site reactions (redness, swelling, or mild pain where the needle goes in) are also common but generally mild and temporary. Cold sores around the mouth (oral herpes reactivation) have been reported at slightly higher rates in some trials. Serious infections or major immune suppression are not a characteristic risk with Dupixent, which distinguishes it from broader-acting immunosuppressants.
Why It Differs From Other Biologics
Several biologic medications treat overlapping conditions like asthma or eczema, but they target different points in the inflammatory cascade. Some block IL-5, which specifically reduces eosinophil counts. Others target IgE directly. Dupixent sits further upstream by blocking IL-4 and IL-13 simultaneously, which affects a broader set of downstream processes: eosinophil recruitment, IgE production, mucus overproduction, and skin barrier disruption all at once. This upstream positioning is why a single drug can be effective across such a wide range of conditions, from skin blistering diseases to lung inflammation to esophageal damage.
It also explains why Dupixent doesn’t work for everyone. If your asthma or other condition isn’t primarily driven by type 2 inflammation, blocking IL-4 and IL-13 won’t address the root cause. This is why doctors typically check for markers of type 2 inflammation, like elevated blood eosinophils, before prescribing it for conditions like asthma or COPD.